|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8500 EUR | +2.91% |
|
+14.09% | +22.48% |
| 06-29 | Valbiotis Raises EUR10 Million for Commercial Development, Working Capital | MT |
| 06-26 | Valbiotis successfully completes a €10.2m capital increase |  |
Company Valuation: Valbiotis
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 66.56 | 44.66 | 62.05 | 23.96 | 16.42 | 20.11 | - |
| Change | - | -32.91% | 38.94% | -61.38% | -31.48% | 22.48% | - |
| Enterprise Value (EV) 1 | 52.33 | 31.01 | 43.91 | 18.1 | 12.83 | 21.31 | 18.01 |
| Change | - | -40.75% | 41.6% | -58.78% | -29.1% | 66.07% | -15.49% |
| P/E | -7.29x | -2.98x | -8.47x | -2.41x | -1.48x | -2.72x | -10.6x |
| PBR | 4.66x | 3.34x | 3.18x | - | - | - | - |
| PEG | - | -0.1x | 0.2x | -0.36x | 0.1x | 0.1x | 0.1x |
| Capitalization / Revenue | 24.7x | 15.9x | 9.11x | 5.16x | 15.7x | 5.22x | 1.52x |
| EV / Revenue | 19.4x | 11x | 6.45x | 3.9x | 12.3x | 5.53x | 1.36x |
| EV / EBITDA | -6.95x | -2.77x | -6.81x | -1.84x | -1.4x | -2.73x | -7.5x |
| EV / EBIT | -6.18x | -2.58x | -6.12x | -1.74x | -1.35x | -2.46x | -3.43x |
| EV / FCF | -7.01x | -3.33x | -5.43x | -1.55x | -1.57x | -2.3x | -1.8x |
| FCF Yield | -14.3% | -30% | -18.4% | -64.6% | -63.8% | -43.4% | -55.5% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.94 | -1.21 | -0.59 | -0.63 | -0.47 | -0.312 | -0.08 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 2.693 | 2.814 | 6.809 | 4.644 | 1.046 | 3.85 | 13.25 |
| EBITDA 1 | -7.534 | -11.17 | -6.444 | -9.836 | -9.198 | -7.8 | -2.4 |
| EBIT 1 | -8.475 | -12.03 | -7.18 | -10.42 | -9.494 | -8.65 | -5.25 |
| Net income 1 | -8.681 | -12.31 | -7.368 | -10.02 | -9.417 | -8.75 | -5.35 |
| Net Debt 1 | -14.23 | -13.65 | -18.14 | -5.861 | -3.586 | 1.2 | -2.1 |
| Reference price 2 | 6.8500 | 3.6000 | 5.0000 | 1.5200 | 0.6940 | 0.8500 | 0.8500 |
| Nbr of stocks (in thousands) | 9,717 | 12,405 | 12,409 | 15,763 | 23,656 | 23,657 | - |
| Announcement Date | 3/15/22 | 3/15/23 | 4/26/24 | 3/3/25 | 3/2/26 | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.72x | 5.53x | -2.73x | - | 23M | |
| 35.82x | 9.04x | 28.05x | 0.05% | 59.1B | |
| 20.71x | 6.39x | 13.83x | 1.45% | 55.19B | |
| -19.36x | 4.94x | -8.63x | -.--% | 24.67B | |
| -42.26x | 14x | -40.82x | -.--% | 24.19B | |
| 24.52x | 4.85x | 12.6x | -.--% | 19.69B | |
| 24.5x | 4.84x | 16.04x | -.--% | 17.56B | |
| 48.53x | 19.97x | 52.67x | 0.06% | 16.22B | |
| 17.56x | 5.1x | 11.91x | -.--% | 14.04B | |
| -520.97x | 35.77x | -3987.51x | -.--% | 14.84B | |
| Average | -41.37x | 11.04x | -390.46x | 0.17% | 24.55B | |
| Weighted average by Cap. | -16.38x | 10.00x | -229.66x | 0.34% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALVAL Stock
- Valuation Valbiotis
Select your edition
All financial news and data tailored to specific country editions
